"Amplimmune develops novel, proprietary biologics that re-balance the human immune system… an important charter that requires dependable funding. By working with InterWest, we’re working with Life Science experts who also have a clear understanding of the entrepreneurial environment. They understand fundraising cycles and provide invaluable guidance to young companies through their most challenging times.”"
LeadershipMichael Richman, President and CEO
Amplimmune develops immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Its founders have identified key immunomodulatory molecules which are the basis for developing a new class of biological treatments that modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients.